Please use this identifier to cite or link to this item:
Title: Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA.
Austin Authors: Brown, Helen;Vansteenkiste, Johan;Nakagawa, Kazuhiko;Cobo, Manuel;John, Thomas ;Barker, Craig;Kohlmann, Alexander;Todd, Alexander;Saggese, Matilde;Chmielecki, Juliann;Markovets, Aleksandra;Scott, Marietta;Ramalingam, Suresh S
Affiliation: Precision Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Respiratory Oncology Unit (Respiratory Diseases), University Hospital KU Leuven, Leuven, Belgium
Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan
Medical Oncology Department, University Regional Hospital of Málaga, IBIMA, Málaga, Spain
Precision Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
Oncology Biometrics, Oncology, AstraZeneca, Cambridge, United Kingdom
Global Medicines Development, Oncology, AstraZeneca, Cambridge, United Kingdom
Translational Medicine, Oncology, AstraZeneca, Waltham, Massachusetts
Precision Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia
Austin Health, Heidelberg, Victoria, Australia
Issue Date: 9-Oct-2019 2019-10-09
Publication information: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019; online first: 9 October
Abstract: Epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC) tumors occasionally express programmed cell death ligand 1 (PD-L1), though frequency and clinical-relevance are not fully characterized. We report PD-L1 expression in patients with EGFRm advanced NSCLC and association with clinical outcomes following treatment with osimertinib or comparator EGFR tyrosine kinase inhibitors in the FLAURA trial (phase III, NCT02296125). Of 231 tissue blocks available from the screened population (including EGFRm positive and negative samples), 197 had sufficient tissue for PD-L1 testing using the SP263 (Ventana) immunohistochemical assay. Tumor cell (TC) staining thresholds of PD-L1 TC≥1%, TC≥25% and TC≥50% were applied. Progression-free survival (PFS) was investigator-assessed, per RECIST 1.1, according to PD-L1 expressors (TC≥1%) or negatives (TC<1%) in randomized patients. PD-L1 staining was successful in 193/197 patient FFPE blocks; of these 128/193 were EGFRm positive and 106/128 patients were randomized to treatment (osimertinib: 54; comparator: 52). At PD-L1 TC≥25% threshold, 8% (10/128) of EGFRm positive tumors expressed PD-L1 versus 35% (23/65) of EGFRm negative tumors. With TC≥1% threshold, 51% (65/128) versus 68% (44/65) were mutation positive and negative respectively, and with the TC≥50% threshold, 5% (7/128) versus 28% (18/65), were mutation positive and negative, respectively. For PD-L1 expressors (TC≥1%), median PFS was 18.4 months with osimertinib and 6.9 months with comparator (HR 0.30 [95% CI: 0.15-0.60]). For PD-L1 negative patients (TC<1%), median PFS was 18.9 months with osimertinib and 10.9 months with comparator (HR 0.37 [95% CI: 0.17-0.74]). Clinical benefit with osimertinib was unaffected by PD-L1 expression status.
DOI: 10.1016/j.jtho.2019.09.009
PubMed URL: 31605792
Type: Journal Article
Subjects: EGFRm
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 25, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.